Literature DB >> 22275222

A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples.

David I Appel1, Bryan Brinda, John S Markowitz, Jeffrey H Newcorn, Hao-Jie Zhu.   

Abstract

A simple, rapid and sensitive method for quantification of atomoxetine by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed. This assay represents the first LC-MS/MS quantification method for atomoxetine utilizing electrospray ionization. Deuterated atomoxetine (d3-atomoxetine) was adopted as the internal standard. Direct protein precipitation was utilized for sample preparation. This method was validated for both human plasma and in vitro cellular samples. The lower limit of quantification was 3 ng/mL and 10 nm for human plasma and cellular samples, respectively. The calibration curves were linear within the ranges of 3-900 ng/mL and 10 nm to 10 µm for human plasma and cellular samples, respectively (r(2)  >0.999). The intra- and inter-day assay accuracy and precision were evaluated using quality control samples at three different concentrations in both human plasma and cellular lysate. Sample run stability, assay selectivity, matrix effect and recovery were also successfully demonstrated. The present assay is superior to previously published LC-MS and LC-MS/MS methods in terms of sensitivity or the simplicity of sample preparation. This assay is applicable to the analysis of atomoxetine in both human plasma and in vitro cellular samples.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275222      PMCID: PMC3391541          DOI: 10.1002/bmc.2706

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  21 in total

1.  Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Jennifer L Donovan; C Lindsay DeVane; Bryan B Gibson; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-09-01       Impact factor: 3.205

2.  Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metabolites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS).

Authors:  John H Mullen; Richard L Shugert; George D Ponsler; Qimin Li; Bhaskar Sundaram; Heather L Coales; Joseph E Yakupkovic; Richard M Lelacheur; William J Wheeler; Frank J Belas; John-Michael Sauer
Journal:  J Pharm Biomed Anal       Date:  2005-07-15       Impact factor: 3.935

3.  A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study.

Authors:  Chaula Patel; Minal Patel; Shubha Rani; Manish Nivsarkar; Harish Padh
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-12-29       Impact factor: 3.205

4.  Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.

Authors:  Ozlem Yildiz; Sahika G Sismanlar; Nursu Cakin Memik; Isik Karakaya; Belma Agaoglu
Journal:  Child Psychiatry Hum Dev       Date:  2011-06

5.  Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.

Authors:  Hao-Jie Zhu; David I Appel; Dirk Gründemann; John S Markowitz
Journal:  J Neurochem       Date:  2010-04-06       Impact factor: 5.372

6.  Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.

Authors:  A Matsui; J Azuma; J W Witcher; A J Long; J-M Sauer; B P Smith; K A DeSante; H A Read; M Takahashi; M Nakano
Journal:  J Clin Pharmacol       Date:  2011-05-04       Impact factor: 3.126

Review 7.  Attention-deficit hyperactivity disorder.

Authors:  Joseph Biederman; Stephen V Faraone
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

8.  Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.

Authors:  Jeffrey H Newcorn; Virginia K Sutton; Margaret D Weiss; Calvin R Sumner
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-05       Impact factor: 8.829

9.  Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS.

Authors:  Eva Choong; Serge Rudaz; Astrid Kottelat; Davy Guillarme; Jean-Luc Veuthey; Chin B Eap
Journal:  J Pharm Biomed Anal       Date:  2009-08-15       Impact factor: 3.935

Review 10.  Clinical pharmacokinetics of atomoxetine.

Authors:  John-Michael Sauer; Barbara J Ring; Jennifer W Witcher
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.